As CEO of Empactful Ventures, Denise Bronner leverages a data-driven approach and over 15 years of industry expertise to empower organizations to redefine their strategies and implement innovative solutions. Drawing on insights from real-world data, she helps companies uncover hidden potential, adapt to evolving landscapes, and position themselves as industry leaders.

Prior to founding Empactful Ventures, Denise earned her PhD in microbiology and immunology from the University of Michigan in 2015. Most recently, she held roles at Johnson & Johnson as Director, Senior Global Feasibility Lead, and Director of Diversity, Equity, and Inclusion in Clinical Trials for their Immunology portfolio.

During our conversation, Denise shared her best practices for designing clinical trials and her perspectives on the importance of diverse patient representation within these trials.

She emphasized involving all key stakeholders—patients, clinicians, advisory boards, and trial site staff—in the design phase because their input can help identify potential design flaws, improve patient recruitment, and create a more robust, patient-centric trial that is also more likely to satisfy regulatory considerations from the FDA.

00:30:20 – Best Practices for Clinical Trials

13:19:08 – Patient Representation in Clinical Trials

27:35:02 – The Benefits, Costs, and Value of Diverse Patient Data

31:27:58 – Clinical Trial Outcomes

34:51:57 – Empactful Ventures

38:14:05- Conclusion